CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients with PAD.

A small Italian study has found an Ozempic-style drug can halve the number of migraine days suffered in a month.

A clinical trial has shown that Ozempic improves blood glucose levels and weight loss in overweight type 1 diabetics who use ...

A NEW weight loss jab that only needs to be taken once monthly leads to “substantial weight loss”, according to early trials.

Please note that Novo Nordisk’s once-weekly subcutaneous diabetes injection, Ozempic, is already approved in 0.25 mg, 0.5 mg, 1 mg and 2 mg doses for treating type II diabetes (T2D) mellitus in ...

Novo Nordisk dropped a pile of scientific data on three new experimental weight-loss drugs, including an oral one, showing what appears to be a strategic "something for everyone" plan of attack from ...

There’s no such thing as "natural Ozempic." While supplements like psyllium, berberine, and glucomannan are paraded as ...

NEW YORK CITY, NY / ACCESS Newswire / July 9, 2025 / Semaglutide is making waves as the powerhouse ingredient in Ozempic and ...

CHMP recommends approval of Novo Nordisk’s Ozempic for peripheral arterial disease: Bagsværd, Denmark Wednesday, June 25, 2025, 15:00 Hrs [IST] Novo Nordisk, a leading global h ...

Novo Nordisk NVO announced that it has submitted a regulatory application to the European Medicines Agency (EMA) seeking ...

Amycretin, a new weight-loss treatment from Novo Nordisk, combines two hunger hormones, helping participants lose nearly ...

"Nearly 62% of adults with type 1 diabetes are either overweight or obese, which is associated with insulin resistance, suboptimal glycemic outcomes, and increased risk for cardio ...